Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

19.04.2018
Drugmakers take unorthodox route to boosting biosimilars by @SarahNev https://t.co/VOpkv7CjUk
17.04.2018
BBA chair Kavya Gopal will be on a panel today at the @BiosimCongress talking on the future of biosimilars with @steinarmadsen, Medical Director, Norwegian Medicines Agency, and Gregory Glover, Principal, Pharmaceutical Law Group PC
16.04.2018
Misinformation on biosimilars undermines patient and prescriber confidence https://t.co/ErzenYUyZG
26.03.2018
@NRAS_UK has a new animation on biosimilars for patients and health professionals https://t.co/6KRdkualcZ
26.03.2018
RT @NRAS_UK: NRAS, @OxfordAHSN and @Sandoz_Global are pleased to launch "Biosimilars, making the switch" - a new animated information video on what to expect when moving from a biologic to a biosimilar. https://t.co/PqJ6FOqYQ1